Chongqing Huapont-in Biotechnology Co., Ltd.

Chongqing Huapont-in Biotechnology Co., Ltd. was established in 2021, which mainly engaged in skin health products area. Established the first skin care brand "SUREAL", and opened a complete "Care" program in the field of skin of Huapont Pharmaceuticals


"SUREAL" brand introduction

SUREAL is the core brand of Chongqing Huapont Pharmaceutical Co., Ltd. (SZ.002004) focusing on functional skin care. It is the business extension of Huapont Pharmaceuticals on the basis of years of deep cultivation of skin medicines and technology advantages.


Brand Advantages

R&D Technology: “SUREAL is a brand of both a drug and cosmetics”, derived from Huapont Pharma's 30 years of experience in skin drug research and development. Huapont Pharma R&D system was established in 1998, there are more than 10,000 square meters of experiment sites, equipped with advanced instruments and equipment with a total value of more than 60 million. There are more than 200 R&D technical personnel (master’s degree or above or senior professional title researchers are more than 60%). It has successfully developed two new drugs of class 1.5 as a representative of topical drugs for skin use, include psoriasis, acne, dermatitis eczema, urticaria and other skin disease drugs. Now there are "Skin Drugs Chongqing Engineering Technology Center", "Retinoic Acid Drugs Engineering Technology Research Center" and other national and ministerial level research and development platform.

Formula Idea: Functional skincare for troubled skin

Formulation Quality: Pharmaceutical management experience


Brand philosophy

Authenticity, freedom, purity


Our products

Acne eradication series:

Azelaic acid cleansing cream; Face balanced water; Cleaning essence lotion

Allergy release series:

Portulaca oleracea multi-functional cream/lotion

Oil-control series:

Multi-functional clear cream/lotion


Basic trademark information

Application/Registration Number: 26453331

Application date: September 7, 2018

International Classification: 3

Exclusivity period: until September 6, 2028